Immuno-oncology is revolutionizing the pharmaceutical industry by leveraging advanced technologies to enhance treatment options. Recent patents, such as those targeting DPP4 for improved lymphocyte trafficking and using IL-7Ra agonist peptides for immune cell growth, are driving significant innovations in the field. Job postings in immuno-oncology have recently grown, and strategic deals have increased, reflecting the industry’s strong focus and investment in developing effective therapies. GlobalData’s immuno-oncology market report provides comprehensive analysis of the market. Buy the report here.
Smarter leaders trust GlobalData
This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding immuno-oncology. It provides an overview of recent developments in immuno-oncology-related deals, talent acquisition, and patent filings within the pharmaceutical industry.
Diverse applications of immuno-oncology in pharmaceutical industry
Pharma companies are leveraging new immuno-oncology technologies through recent patents to innovate and improve cancer treatment. The Pasteur Institute's patent focuses on enhancing tumor immunity and immunotherapy by inhibiting Dipeptidylpeptidase 4 (DPP4) to improve lymphocyte trafficking. Medikine Inc's patent involves using IL-7Ra?c agonist peptides in cell manufacturing to selectively grow immune cell populations for immunotherapy. Additionally, HuBit genomix Inc's patent offers a method for preventing allergic disorders in infants through IgE-class-specific immunosuppression. These patents showcase advancements in targeting cancer cells and enhancing immune responses, offering potential benefits for the acquirer in developing more effective and targeted Immuno-Oncology therapies.
The industry experienced a 20% decline in the number of immuno-oncology-related patent applications in Q1 2024 compared with the previous quarter. On an annual basis, the number of immuno-oncology-related patent applications in the pharmaceutical industry witnessed a drop of 10% compared with Q1 2023.
Strategic deal trends in immuno-oncology in pharmaceutical industry
Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in immuno-oncology. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of immuno-oncology in the pharmaceutical industry.
In Q1 2024, the number of immuno-oncology-related deals in the pharmaceutical industry declined by 11% compared with Q1 2023. On a quarterly basis, there was 12% increase in the number of deals in Q1 2024 compared with the previous quarter.
Impact on hiring
In terms of new job posting, in Q1 2024, the pharmaceutical industry experienced a 24% growth compared with the previous quarter. On an annual basis, job postings also declined by 7%. Notably, management occupations, with a share of 28%, emerged as the top immuno-oncology-related job roles within the pharmaceutical industry in Q1 2024, with new job postings rising by 44% quarter-on-quarter. Life, physical, and social science occupations came in second with a share of 24% in Q1 2024, with new job postings dropping by 26% over the previous quarter. The other prominent immuno-oncology roles include business and financial operations occupations with a 5% share in Q1 2024, and healthcare practitioners and technical occupations with a 4% share of new job postings.
Dendreon Pharmaceuticals, MallInckrodt, ImmunityBio, AstraZeneca, and BioNTech are among the top companies leading in immuno-oncology hiring within the pharmaceutical industry.
Countries driving adoption of immuno-oncology in pharmaceutical industry
The US is the leading country in immuno-oncology adoption within the pharmaceutical industry, boasting the highest number of immuno-oncology-related patents, jobs, and deals. Meanwhile, China, Australia, Canada and South Korea also maintain significant positions in immuno-oncology adoption within the pharmaceutical industry.
In conclusion, immuno-oncology is transforming the pharmaceutical industry through innovative patents and strategic investments, driving advancements in treatment options. The increasing focus on this field is reflected in the trends of rising job postings and strategic deals, highlighting its growing importance and impact.
To further understand GlobalData's analysis on immuno-oncology in the pharmaceutical industry, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData patent analytics tracks patent filings and grants across companies and themes. Proprietary databases on deals and job analytics are used to respectively monitor global deal activity and uncover insights from daily job postings to identify trends, company activities, and industry dynamics across different sectors globally.
